A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Trial Profile

A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Denileukin diftitox (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Eisai Inc
  • Most Recent Events

    • 20 Apr 2015 Planned End Date changed from 1 Aug 2014 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
    • 21 Aug 2014 Planned End Date changed from 1 Jul 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
    • 17 Jul 2014 Planned End Date changed from 1 Jun 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top